John C. Jacobs served as the CEO of Harmony Biosciences from November 2020 until his resignation in January 2023. His leadership came during a critical period for the company, which saw significant growth, particularly with its main product, WAKIX, aimed...

John C. Jacobs served as the CEO of Harmony Biosciences from November 2020 until his resignation in January 2023. His leadership came during a critical period for the company, which saw significant growth, particularly with its main product, WAKIX, aimed at treating narcolepsy. Jacobs has been recognized for driving strong commercial results, including over $437 million in revenue in 2022, a notable 43% increase from the previous year. Before heading Harmony, he held various roles in the pharmaceutical industry, including at Teva Pharmaceuticals, where he was the Senior Vice President and General Manager of Respiratory. His career spans over 25 years in various marketing and operations roles within major companies such as Pfizer and Wyeth. Despite his impressive financial contributions, Jacobs did not receive a bonus for his final year, reflecting his departure before bonuses were issued. His departure was not due to performance issues; he left to pursue other opportunities, showcasing a willingness to adapt to new challenges. Jacobs holds an MBA and a Bachelor’s degree in business, underpinning his strong business acumen.